Skip to main content
. 2016 Feb 23;53:210–219. doi: 10.1007/s12020-016-0895-8

Fig. 2.

Fig. 2

Effect of pasireotide LAR and active control on a FPG and b HbA1c levels in all patients, patients receiving antidiabetic medication at any time point, patients not receiving antidiabetic medication, patients receiving antidiabetic medication at baseline, and patients starting antidiabetic medication post-baseline. Data presented as geometric mean and 68 % CI. Inset values represent patient numbers at 24 weeks